Loading clinical trials...
Loading clinical trials...
The number of metastases in a patient with primary or recurrent prostate cancer has major prognostic implication. The purpose is to compare, in a pilot study, the diagnostic performance of 18F-NaF-PE...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Valentina Garibotto
Collaborators
NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
NCT07580196 · Prostate Cancer
NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Geneva University Hospital
Geneva
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions